Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Other Chemical drugs >  Rimegepant sulfate

Rimegepant sulfate

Basic information Safety Supplier Related

Rimegepant sulfate Basic information

Product Name:
Rimegepant sulfate
Synonyms:
  • [(5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl]4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate
  • (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate hemisulfate sesquihydrate
  • RIMEGEPANT SULFATE
  • Rimegepant sulfate hydrate【Chemical name:1-Piperidinecarboxylic acid, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-, (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl ester, sulfate, hydrate (2:1:3)】
  • (5S,6S,9R)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b] pyridin-9-yl4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate sesquihydrate
  • Rimegepant sulfate hydrate
  • Rimegepant hemisulfate sesquihydrate
  • Rimegepant 1/2Sulfate 3/2Trihydrate
CAS:
1374024-48-2
MF:
C28H30F2N6O7S
MW:
632.64
EINECS:
822-372-0
Product Categories:
  • API
Mol File:
1374024-48-2.mol
More
Less

Rimegepant sulfate Chemical Properties

InChI
InChI=1/C28H28F2N6O3.H2O4S/c29-20-6-1-4-17(23(20)30)18-8-9-22(25-19(24(18)31)5-2-12-32-25)39-28(38)35-14-10-16(11-15-35)36-21-7-3-13-33-26(21)34-27(36)37;1-5(2,3)4/h1-7,12-13,16,18,22,24H,8-11,14-15,31H2,(H,33,34,37);(H2,1,2,3,4)/t18-,22+,24-;/s3
InChIKey
SBWRYPRKGHWPOH-FDZFFRPLNA-N
SMILES
S(O)(O)(=O)=O.O=C1NC2=NC=CC=C2N1C1CCN(C(=O)O[C@@H]2CC[C@@H](C3C=CC=C(F)C=3F)[C@H](N)C3=CC=CN=C23)CC1 |&1:22,25,34,r|
More
Less

Rimegepant sulfate Usage And Synthesis

Description

Rimegepant sulfate is a small molecule, highly selective calcitonin gene-related peptide antagonist (CGRP) developed by Biohaven Pharmaceutical Holdings, Inc. and approved by the FDA for the acute treatment of migraine. rimegepant and ubrogepant are the only CGRP antagonists with oral bioavailability. Because of the absence of vasoconstrictive properties observed with oral CGRP antagonists, the use of rimegepant is safer and more reliable in patients with contraindications to standard therapy[1].

Side effects

Common side effects of Rimegepant sulfate are nausea, which may be severe enough to cause shortness of breath, difficulty breathing; swelling of the face, eyes, mouth, throat, tongue, or lips; rash, measles; and itching.

Synthesis

Rimegepant sulfate is prepared by the reaction of rimegepant and water.
Step: With sulfuric acid In ethanol at 20 - 70℃; Solvent; Temperature.

References

[1] J S. Rimegepant: First Approval.[J]. Drugs, 2020, 80 7: 741-746. DOI:10.1007/s40265-020-01301-3.

Rimegepant sulfateSupplier

Taizhou Yuxin Biotechnology Co., Ltd., Gold
Tel
+86-0576--88902229 +86-13968687450
Email
yuxin@yuxchem.com
Nanjing Vcare PharmaTech Co., Ltd Gold
Tel
025-58741518 13327700685
Email
sales@vcarepharmatech.com
ChengDu TongChuangYuan Pharmaceutical Co.Ltd Gold
Tel
028-83379370 13880556291
Email
tcy@tcypharm.com
Porton Pharma Solutions Ltd. Gold
Tel
23-86083200-6540
Email
jia.chen@portonpharma.com
CHANGZHOU PHARMACEUTICAL FACTORY Gold
Tel
519-88821493 18915891730
Email
shm@czpharma.com